Investigating Gram-negative bacilli isolates’ sensitivity to ceftazidime/avibactam

Background: Multidrug resistant (MDR) Gram negative organisms are becoming increasingly common. Carbapenem resistant Enterobacterales (CRE) pose a major threat and necessitate the development of new antibiotics. MDR and carbapenem resistant infections, which are common in intensive care units and ho...

Full description

Saved in:
Bibliographic Details
Main Authors: Sunali, Mithilesh Kumar Jha, Mukesh Kumar, Maneesh Kumar, Nishant Ranjan
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2025-01-01
Series:Journal of Family Medicine and Primary Care
Subjects:
Online Access:https://journals.lww.com/10.4103/jfmpc.jfmpc_1272_24
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823858122783981568
author Sunali
Mithilesh Kumar Jha
Mukesh Kumar
Maneesh Kumar
Nishant Ranjan
author_facet Sunali
Mithilesh Kumar Jha
Mukesh Kumar
Maneesh Kumar
Nishant Ranjan
author_sort Sunali
collection DOAJ
description Background: Multidrug resistant (MDR) Gram negative organisms are becoming increasingly common. Carbapenem resistant Enterobacterales (CRE) pose a major threat and necessitate the development of new antibiotics. MDR and carbapenem resistant infections, which are common in intensive care units and hospitals, lead to increased morbidity, mortality, prolonged hospital stays, and higher healthcare costs. New antimicrobials such as ceftazidime avibactam offer potential alternatives to conventional treatments such as tigecycline and colistin, which have significant side effects and limitations. Aim: This study focuses on the antibiotic susceptibility of ceftazidime/ avibactam to Gram negative bacilli found in a large number of clinical samples collected from a tertiary care facility in Netaji Subhas Medical University and Hospital, Bihta, India. Methodology: The study included 81 Gram negative bacteria isolated from patient samples. Based on the Clinical Laboratory Standards Institute guidelines mentioned in the Kirby Bauer disc diffusion method. Result and Conclusion: the results showed that ceftazidime avibactam inhibited 89.9% of the Enterobacteriaceae isolates, which was higher than the 80.3% of amikacin and the 85.1% of meropenem. Ceftazidime avibactam was effective against CRE isolates in 69.9% of cases and against MDR isolates in urine in 94% of cases, which was higher than the 40% of ceftriaxone and 94% of nitrofurantoin. The results show that ceftazidime avibactam can cure MDR and CRE infections, especially urinary tract infections, better than conventional antibiotics, which is a great help in the fight against increasing antibiotic resistance.
format Article
id doaj-art-6aa432bf1c834f63bd2c2574b192b300
institution Kabale University
issn 2249-4863
2278-7135
language English
publishDate 2025-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Journal of Family Medicine and Primary Care
spelling doaj-art-6aa432bf1c834f63bd2c2574b192b3002025-02-11T13:53:51ZengWolters Kluwer Medknow PublicationsJournal of Family Medicine and Primary Care2249-48632278-71352025-01-0114131131610.4103/jfmpc.jfmpc_1272_24Investigating Gram-negative bacilli isolates’ sensitivity to ceftazidime/avibactamSunaliMithilesh Kumar JhaMukesh KumarManeesh KumarNishant RanjanBackground: Multidrug resistant (MDR) Gram negative organisms are becoming increasingly common. Carbapenem resistant Enterobacterales (CRE) pose a major threat and necessitate the development of new antibiotics. MDR and carbapenem resistant infections, which are common in intensive care units and hospitals, lead to increased morbidity, mortality, prolonged hospital stays, and higher healthcare costs. New antimicrobials such as ceftazidime avibactam offer potential alternatives to conventional treatments such as tigecycline and colistin, which have significant side effects and limitations. Aim: This study focuses on the antibiotic susceptibility of ceftazidime/ avibactam to Gram negative bacilli found in a large number of clinical samples collected from a tertiary care facility in Netaji Subhas Medical University and Hospital, Bihta, India. Methodology: The study included 81 Gram negative bacteria isolated from patient samples. Based on the Clinical Laboratory Standards Institute guidelines mentioned in the Kirby Bauer disc diffusion method. Result and Conclusion: the results showed that ceftazidime avibactam inhibited 89.9% of the Enterobacteriaceae isolates, which was higher than the 80.3% of amikacin and the 85.1% of meropenem. Ceftazidime avibactam was effective against CRE isolates in 69.9% of cases and against MDR isolates in urine in 94% of cases, which was higher than the 40% of ceftriaxone and 94% of nitrofurantoin. The results show that ceftazidime avibactam can cure MDR and CRE infections, especially urinary tract infections, better than conventional antibiotics, which is a great help in the fight against increasing antibiotic resistance.https://journals.lww.com/10.4103/jfmpc.jfmpc_1272_24carbapenem-resistantceftazidime-avibactamenterobacteralesgram-negative bacillikirby-bauer disc diffusionmultidrug-resistant
spellingShingle Sunali
Mithilesh Kumar Jha
Mukesh Kumar
Maneesh Kumar
Nishant Ranjan
Investigating Gram-negative bacilli isolates’ sensitivity to ceftazidime/avibactam
Journal of Family Medicine and Primary Care
carbapenem-resistant
ceftazidime-avibactam
enterobacterales
gram-negative bacilli
kirby-bauer disc diffusion
multidrug-resistant
title Investigating Gram-negative bacilli isolates’ sensitivity to ceftazidime/avibactam
title_full Investigating Gram-negative bacilli isolates’ sensitivity to ceftazidime/avibactam
title_fullStr Investigating Gram-negative bacilli isolates’ sensitivity to ceftazidime/avibactam
title_full_unstemmed Investigating Gram-negative bacilli isolates’ sensitivity to ceftazidime/avibactam
title_short Investigating Gram-negative bacilli isolates’ sensitivity to ceftazidime/avibactam
title_sort investigating gram negative bacilli isolates sensitivity to ceftazidime avibactam
topic carbapenem-resistant
ceftazidime-avibactam
enterobacterales
gram-negative bacilli
kirby-bauer disc diffusion
multidrug-resistant
url https://journals.lww.com/10.4103/jfmpc.jfmpc_1272_24
work_keys_str_mv AT sunali investigatinggramnegativebacilliisolatessensitivitytoceftazidimeavibactam
AT mithileshkumarjha investigatinggramnegativebacilliisolatessensitivitytoceftazidimeavibactam
AT mukeshkumar investigatinggramnegativebacilliisolatessensitivitytoceftazidimeavibactam
AT maneeshkumar investigatinggramnegativebacilliisolatessensitivitytoceftazidimeavibactam
AT nishantranjan investigatinggramnegativebacilliisolatessensitivitytoceftazidimeavibactam